SHH and neoplasm: In this preclinical study, we investigated if this innovative strategy is also effective in vivo using orthotopic patient-derived xenograft (PDX) models for a SHH/TP53-mutated (SHH/TP53-mut) and a non-WNT/non-SHH, MYC-amplificated Group 3 (Group 3) MB tumor, representing two high-risk MB subtypes.